183 related articles for article (PubMed ID: 18599064)
1. Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors.
Sankatsing RR; Wit FW; Vogel M; de Groot E; Brinkman K; Rockstroh JK; Kastelein JJ; Stroes ES; Reiss P
Atherosclerosis; 2009 Feb; 202(2):589-95. PubMed ID: 18599064
[TBL] [Abstract][Full Text] [Related]
2. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.
Currier JS; Kendall MA; Zackin R; Henry WK; Alston-Smith B; Torriani FJ; Schouten J; Mickelberg K; Li Y; Hodis HN;
AIDS; 2005 Jun; 19(9):927-33. PubMed ID: 15905673
[TBL] [Abstract][Full Text] [Related]
3. [Effect of antiretroviral therapy on carotid intima-media thickness in HIV-infected patients].
Ferraro S; Paolillo S; Gargiulo M; Costanzo P; Maggi P; Chirianni A; Chiariello M; Filardi PP
G Ital Cardiol (Rome); 2009 Sep; 10(9):596-601. PubMed ID: 19891251
[TBL] [Abstract][Full Text] [Related]
4. Carotid intima-media thickness in HIV patients treated with antiretroviral therapy.
Lebech AM; Wiinberg N; Kristoffersen US; Hesse B; Petersen CL; Gerstoft J; Kjaer A
Clin Physiol Funct Imaging; 2007 May; 27(3):173-9. PubMed ID: 17445068
[TBL] [Abstract][Full Text] [Related]
5. Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy.
Jeong SJ; Kim CO; Song YG; Baek JH; Kim SB; Jin SJ; Ku NS; Han SH; Choi JY; Lee HC; Kim JM
Atherosclerosis; 2011 Dec; 219(2):778-83. PubMed ID: 21872861
[TBL] [Abstract][Full Text] [Related]
6. Low prevalence of high-density lipoprotein cholesterol level < 1 mmol/L in non-nucleoside reverse transcriptase inhibitor recipients.
Bergersen BM; Tonstad S; Sandvik L; Bruun JN
Int J STD AIDS; 2005 May; 16(5):365-9. PubMed ID: 15949067
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
8. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
9. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
[TBL] [Abstract][Full Text] [Related]
10. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
11. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
12. Carotid intimal medial thickness in human immunodeficiency virus-infected women: effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome.
Johnsen S; Dolan SE; Fitch KV; Kanter JR; Hemphill LC; Connelly JM; Lees RS; Lee H; Grinspoon S
J Clin Endocrinol Metab; 2006 Dec; 91(12):4916-24. PubMed ID: 17003092
[TBL] [Abstract][Full Text] [Related]
13. HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease.
Lekakis J; Tsiodras S; Ikonomidis I; Palios J; Poulakou G; Rallidis L; Antoniadou A; Panagopoulos P; Papadopoulos A; Giamarellou H; Kremastinos DT
Clin Sci (Lond); 2008 Sep; 115(6):189-96. PubMed ID: 18251713
[TBL] [Abstract][Full Text] [Related]
14. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children.
McComsey GA; O'Riordan M; Hazen SL; El-Bejjani D; Bhatt S; Brennan ML; Storer N; Adell J; Nakamoto DA; Dogra V
AIDS; 2007 May; 21(8):921-7. PubMed ID: 17457085
[TBL] [Abstract][Full Text] [Related]
15. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
16. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
[TBL] [Abstract][Full Text] [Related]
17. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K; Pedro RJ; Latiff GH; Conradie F; Domingo P; Lupo S; Pumpradit W; Vingerhoets JH; Peeters M; Peeters I; Kakuda TN; De Smedt G; Woodfall B;
HIV Med; 2008 Nov; 9(10):883-96. PubMed ID: 18795960
[TBL] [Abstract][Full Text] [Related]
18. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis.
Sombogaard F; Franssen EJF; Terpstra WE; Kerver ED; van den Berk GEL; Crul M
Int J Clin Pharm; 2018 Oct; 40(5):1402-1408. PubMed ID: 29948741
[TBL] [Abstract][Full Text] [Related]
19. Arterial stiffness and carotid intima-media thickness in HIV infected patients.
Papita A; Albu A; Fodor D; Itu C; Cârstina D
Med Ultrason; 2011 Jun; 13(2):127-34. PubMed ID: 21655539
[TBL] [Abstract][Full Text] [Related]
20. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
